Unlike their predecessors—mAbs of animal origin, or humanized or synthetic mAbs—YUMAB’s fully human mAbs maximize epitope diversity while minimizing immunogenicity and thus adverse effects.

Monoclonal antibodies (mAbs) can achieve unparalleled affinity and specificity for a wide range of biomolecules, making the reagents critical to both basic and clinical research. The vast majority ...

Published in the peer-reviewed journal mAbs, the study presents nipocalimab's high-affinity binding to the neonatal Fc receptor (FcRn) and its capability to significantly reduce IgG levels ...

During the last three months, 5 analysts shared their evaluations of Y-mAbs Therapeutics (NASDAQ:YMAB), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a ...